CurrentBlue Cross Blue Shield - Rhode IslandPolicy 3.03.03

Medical Coverage Policy Prescription Digital Health Therapies for Attention Deficit/Hyperactivity Disorder

Policy addresses coverage of prescription digital health therapies for attention-deficit/hyperactivity disorder (ADHD) for Medicare Advantage and commercial products, evaluating medical necessity and coverage status of such digital therapeutics (e.g., EndeavorRx).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Prescription Digital Health Therapies for Attention Deficit/Hyperactivity Disorder

Policy CodePolicy 3.03.03

Change TypeNo material change

Effective DateJan 1, 2022

Next Review Date

Key ActionVerify member-specific benefits in the Benefit Booklet/Evidence of Coverage/Subscriber Agreement and confirm coverage before providing prescription digital therapy for ADHD.

SourceLink

POLICY UPDATE CHANGES

No material clinical/coverage changes — policy remains unchanged.

1Coverage Stance: Not Covered Indications

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy addresses coverage of prescription digital health therapies for attention-deficit/hyperactivity disorder (ADHD), with a focus on the prescription digital therapeutic device EndeavorRx. The target population described is children with ADHD (specifically ages 8-12 years with primarily inattentive or combined type). The policy's high-level stance is that such prescription digital therapies (including EndeavorRx) are not covered / not medically necessary for Medicare Advantage and commercial products due to insufficient evidence to determine effects on health outcomes.

Coverage Determination

Coverage statements as provided in the policy:

ALL of the following

Medicare Advantage Plans: Prescription digital therapy for the treatment of attention-deficit/hyperactivity disorder is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.
Commercial Products: Not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Policy metadata

policy_number3.03.03

effective date01/01/2022

last_review09/01/2021

statusCURRENT

coverage_stanceNot covered / Not medically necessary for Medicare Advantage and Commercial Products (insufficient evidence)

Medical-Necessity Rationale & Evidence

FDA clearance: EndeavorRx (Akili Interactive Labs) received De Novo marketing clearance (DEN200026) in April 2020 as a prescription device indicated to improve attention function in children ages 8-12 years with primarily inattentive or combined type ADHD; improvements were measured by computerized tests (e.g., TOVA).

Policy evidence assessment: The policy concludes there is insufficient evidence to determine the effects of the technology on health outcomes; therefore the therapy is not covered for Medicare Advantage plans and considered not medically necessary for commercial products.

EndeavorRx: A prescription digital therapeutic (computer game) cleared by the FDA via De Novo (DEN200026) intended to improve attention function in children ages 8-12 years with primarily inattentive or combined type ADHD; effectiveness was demonstrated on digitally assessed measures (e.g., TOVA) of sustained and selective attention.

Coding

No specific codesmixedNot Covered

No codes listed

Provider Actions & Billing Impact

Documentation Required

Benefit verification required

Benefits may vary between groups and contracts; providers should refer to the member's Benefit Booklet/Evidence of Coverage/Subscriber Agreement for applicable coverage determinations and verify member-specific benefits.

Denial Risk

Service not covered / not medically necessary

Claims for prescription digital therapy for ADHD may be denied because the service is considered not covered / not medically necessary per this policy due to insufficient evidence.

There is no billing code for this non-covered service. Claims may be denied because the service is considered not covered / not medically necessary per this policy. Providers may not bill members for non-covered services unless the member was informed and agreed in writing in advance per participation/subscriber agreements; verify member-specific benefits in the member's Benefit Booklet/Evidence of Coverage/Subscriber Agreement.

Background

ADHD is characterized by symptoms of hyperactivity, impulsivity, and inattention that are excessive for the person's age. Established treatments for children with ADHD include educational, environmental, psychological/behavioral interventions, and medication. In April 2020, the FDA granted De Novo marketing clearance (DEN200026) for EndeavorRx, a prescription digital therapeutic intended to improve attention function in children ages 8-12 with primarily inattentive or combined type ADHD; benefits were measured by computerized attention tests, and the device is intended to be used as part of a therapeutic program that may include clinician-directed medication and/or educational programs.

Revision History

2022-01-01Effective DateLatest

Policy effective date

2021-09-01Last Review

Policy last updated / last review date